期刊文献+

非酒精性脂肪性肝病相关分子机制的研究进展 被引量:4

Research Progress in Molecular Mechanism of Non-alcoholic Fatty Liver Disease
下载PDF
导出
摘要 非酒精性脂肪性肝病(NAFLD)已成为目前全球最流行的肝病之一,其发生与不良生活方式、胰岛素抵抗、遗传以及代谢应激密切相关。NAFLD发生的潜在机制复杂,涉及各种细胞介质及相关信号通路、内质网应激以及细胞自噬等病理过程。从单纯性脂肪肝到非酒精性脂肪性肝炎,再到肝纤维化和晚期肝硬化等,目前临床可直接用于治疗NAFLD的药物较少。因此,了解NAFLD发生的分子机制及相关信号通路在其发展过程中的作用,对临床治疗具有重要意义。 Non-alcoholic fatty liver disease(NAFLD)has become one of the most popular liver diseases in the world.The occurrence of NAFLD is closely related to bad lifestyle,insulin resistance,heredity and metabolic stress.The underlying mechanism of NAFLD is complex,involving a variety of cellular mediators and related signal pathways,endoplasmic reticulum stress and cell autophagy and other pathological processes.From simple fatty liver to non-alcoholic steatohepatitis,and then to liver fibrosis and end-stage liver cirrhosis,there are few drugs that can be directly used to treat NAFLD.Therefore,it is of great significance for the clinical treatment to understand the molecular mechanism of NAFLD and the role of related signal pathways in its development.
作者 邓威 陈倩 郭金 张璐懿 石春霞 龚作炯 DENG Wei;CHEN Qian;GUO Jin;ZHANG Luyi;SHI Chunxia;GONG Zuojiong(Department of Infectious Disease,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处 《医学综述》 CAS 2022年第7期1272-1277,共6页 Medical Recapitulate
基金 国家自然科学基金(82070609)。
关键词 非酒精性脂肪性肝病 分子机制 信号通路 Non-alcoholic fatty liver disease Molecular mechanism Signal pathways
  • 相关文献

参考文献3

二级参考文献44

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华糖尿病杂志,2010,2(1). 被引量:525
  • 2Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, CusiK, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholicfatty liver disease: practice Guideline by the AmericanAssociation for the Study of Liver Diseases, American Collegeof Gastroenterology, and the American GastroenterologicalAssociation. Hepatology 2012; 55: 2005-2023 [PMID: 22488764DOI: 10.1002/hep.25762].
  • 3Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liverdisease and hepatocellular carcinoma: a weighty connection.Hepatology 2010; 51: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep.23594].
  • 4Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is themost rapidly growing indication for liver transplantation in patientswith hepatocellular carcinoma in the U.S. Hepatology 2014; 59:2188-2195 [PMID: 24375711 DOI: 10.1002/hep.26986].
  • 5Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ,Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-AridaA, Yeh M, McCullough AJ, Sanyal AJ. Design and validation ofa histological scoring system for nonalcoholic fatty liver disease.Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701].
  • 6Pagadala MR, McCullough AJ. The relevance of liver histologyto predicting clinically meaningful outcomes in nonalcoholicsteatohepatitis. Clin Liver Dis 2012; 16: 487-504 [PMID: 22824477DOI: 10.1016/j.cld.2012.05.006].
  • 7Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, YounoszaiZ, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholicsteatohepatitis: interprotocol agreement and ability to predictliver-related mortality. Hepatology 2011; 53: 1874-1882 [PMID:21360720 DOI: 10.1002/hep.24268].
  • 8Jin X, Chen YP, Kong M, Zheng L, Yang YD, Li YM. Transitionfrom hepatic steatosis to steatohepatitis: unique microRNA patternsand potential downstream functions and pathways. J GastroenterolHepatol 2012; 27: 331-340 [PMID: 21793903 DOI: 10.1111/j.1440-1746.2011.06864.x].
  • 9Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fattyliver disease: novel biomarkers and prognostic tools during thetransition from steatosis to hepatocarcinoma. Biomed Res Int 2014;2014: 741465 [PMID: 24745023 DOI: 10.1155/2014/741465].
  • 10Alvarez ML, DiStefano JK. Towards microRNA-based therapeuticsfor diabetic nephropathy. Diabetologia 2013; 56: 444-456 [PMID:23135222 DOI: 10.1007/s00125-012-2768-x].

共引文献20

同被引文献53

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部